• Novo Nordisk A/S, of Bagsvaerd, Denmark, said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-4 in favor of approving insulin degludec and insulin degludec/insulin aspart with a post-approval cardiovascular outcomes trial commitment.